普外病区围手术期应用质子泵抑制剂预防应激性溃疡的合理性分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the rationality of proton pump inhibitors (PPIs) in the prevention of stress ulcers (SU)in general surgery areas. Methods The clinical data of 264 patients who used PPIs during the perioperative period in the general surgery area of Sihong County People′s Hospital in August 2020 were retrospectively selected, and the disease severity, basic patient information, surgical status, and PPIs use status were screened according to the selection criteria. The rationality of PPIs medication were comprehensively evaluate. Results Among the 128 selected PPIs medical records, 4 types of PPIs were mainly involved, including omeprazole (injection), esomeprazole (injection), rabeprazole (injection), pantoprazole (injection). A total of 128 cases of preventive use of PPIs during the perioperative period were screened. There were 61 cases of irrational use of drugs, accounting for 47.66%, of which 16 cases (26.23%) were problematic in the route of medication, 32 cases (52.46%) were used without indications, and the course of medication was used. 8 cases (13.11%) were too long, 2 cases (3.28%) were incorrect in usage and dosage, and 3 cases (4.92%)had drug interactions. Conclusion When PPIs were used to prevent SU in this ward, there are unindicated medications,unsuitable selection of varieties and routes of administration, and unreasonable treatments. Relevant departments of the hospital should attach great importance to standardizing the rational use of PPIs.

Key words： Proton pump inhibitor Stress ulcer Prevention Rational analysis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Jing
	LI Lin-na

Cite this article:

ZHAO Jing,LI Lin-na. Analysis of the rationality of proton pump inhibitors in the prevention of stress ulcers in the perioperative period in general surgery areas[J]. 中国当代医药, 2021, 28(28): 157-159.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I28/157

[1]	李勉力，张伟健，郭玲珑，等.沃诺拉赞对比质子泵抑制剂治疗反流性食管炎有效性和安全性的Meta 分析[J].中国全科医学，2021，24（6）：712-717.
[2]	中华人民共和国国家卫生健康委员会.质子泵抑制剂临床应用指导原则（2020年版）[J].中国实用乡村医生杂志，2021，28（1）：1-9.
[3]	高洁，朱瑾.胃肠道手术患者使用质子泵抑制剂的合理性评价[J].中国现代应用药学，2021，38（1）：104-107.
[4]	柏愚，李延青，任旭，等.应激性溃疡防治专家建议（2018版）[J].中华医学杂志，2018，98（42）：3392．
[5]	李莉，邵兵，刘琳琳，等.质子泵抑制剂在预防外科手术患者围手术期应激性溃疡的应用分析[J].实用药物与临床，2021，24（2）：142-145.
[6]	袁洪.湖南省质子泵抑制剂的临床应用指导原则（试行）[J].中南药学，2016，14（7）：673-683.
[7]	质子泵抑制剂预防性应用专家共识写作组.质子泵抑制剂预防性应用专家共识（2018）[J].中国医师杂志，2018，20（12）：1775-1781.
[8]	孙晨，刘立民，朱旭，等.质子泵抑制剂对大剂量甲氨蝶呤排泄延迟影响的研究现状[J].中国临床药理学杂志，2021，37（6）：764-767.
[9]	冯小雪，燕忠生.质子泵抑制剂对消化道微生态影响的生物学机制[J].中国微生态学杂志，2021，33（1）：116-119，封3.
[10]	国家药典委员会．中华人民共和国药典：临床用药须知[S]．北京：中国医药科技出版社，2011：366－372．
[11]	赵霞，张伶俐.《临床药物治疗学》[M].北京：人民卫生出版社，2016：168-169.
[12]	刘琨，刘蜀宝.《新编药物学》（第17 版）简评[J].中南药学，2014，12（9）：940-942.
[13]	赵玉沛. 应激性黏膜病变预防与治疗——中国普通外科专家共识（2015）[J].中国实用外科杂志，2015，（7）：728-730.
[14]	王佳，李丹滢，葛卫红.注射用质子泵抑制剂预防应激性溃疡的应用现状与挑战[J].药学与临床研究，2020，28（6）：451-454，458.
[15]	毛旭峰，杨樟卫.质子泵抑制剂临床超适应证使用的医疗大数据分析[J].药学实践杂志，2020，38（2）：184-188.
[16]	Vernaz N，Rollason V，Adlere L，et al.Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines[J].Pharmacol Res Perspect，2016，4（3）：e234.